$5.59
Annexon Inc is a biotechnology business based in the US. Annexon Inc shares (ANNX) are listed on the NASDAQ and all prices are listed in US Dollars. Annexon Inc employs 71 staff and has a market cap (total outstanding shares value) of 0.00.
Our top picks for where to buy Annexon Inc stock
How to buy Annexon Inc stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ANNX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Annexon Inc stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Annexon Inc stock price (NASDAQ: ANNX)
Use our graph to track the performance of ANNX stocks over time.Annexon Inc shares at a glance
Latest market close | $5.41 |
---|---|
52-week range | $1.57 - $8.40 |
50-day moving average | $5.61 |
200-day moving average | $4.94 |
Wall St. target price | $16.40 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-1.21 |
Is it a good time to buy Annexon Inc stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Annexon Inc price performance over time
Historical closes compared with the close of $5.41 from 2024-09-03
1 week (2024-08-29) | -8.77% |
---|---|
1 month (2024-08-05) | 5.41 |
3 months (2024-06-05) | -20.32% |
6 months (2024-03-05) | 1.12% |
1 year (2023-09-05) | 101.87% |
---|---|
2 years (2022-09-01) | N/A |
3 years (2021-09-03) | 17.15 |
5 years (2019-09-01) | N/A |
Annexon Inc financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -24.83% |
Return on equity TTM | -42.2% |
Profit margin | 0% |
Book value | $3.42 |
Market Capitalization | $602.2 million |
TTM: trailing 12 months
Annexon Inc share dividends
We're not expecting Annexon Inc to pay a dividend over the next 12 months.
Annexon Inc share price volatility
Over the last 12 months, Annexon Inc's shares have ranged in value from as little as $1.57 up to $8.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Annexon Inc's is 1.278. This would suggest that Annexon Inc's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Annexon Inc overview
Annexon, Inc. , a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California. .
Frequently asked questions
nullWhat percentage of Annexon Inc is owned by insiders or institutions?
Currently 0.389% of Annexon Inc shares are held by insiders and 104.117% by institutions. How many people work for Annexon Inc?
Latest data suggests 71 work at Annexon Inc. When does the fiscal year end for Annexon Inc?
Annexon Inc's fiscal year ends in December. Where is Annexon Inc based?
Annexon Inc's address is: 1400 Sierra Point Parkway, Brisbane, CA, United States, 94005 What is Annexon Inc's ISIN number?
Annexon Inc's international securities identification number is: US03589W1027
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question